A Blood Biomarker‐guided Precision Medicine Approach for Individualized Neurodegenerative Disease Risk Reduction and Treatment: The Future of Preventive Neurology?
The study concluded that higher compliance to interventions led to more significant changes in protein markers. Multi-modal interventions were most effective. Novel alpha-synuclein markers also changed, potentially aiding in evaluating interventions for Lewy Body Dementia and Parkinson's disease. These markers may serve as future outcome measures for preventive neurology care.
Authors
- Beth A. Lewis (ORCID: https://orcid.org/0000-0002-6034-568X)
- Richard Isaacson (ORCID: https://orcid.org/0000-0002-0949-6204)
- Praveen Parthasarathy (ORCID: https://orcid.org/0000-0002-5910-9452)
- Diana Saville
- Licet Valois
- Nicholas M. Clute‐Reinig
- Philip Sisser
- Alon Seifan (ORCID: https://orcid.org/0000-0001-6470-3600)
- Michael John McCullough (ORCID: https://orcid.org/0000-0001-7829-4684)
- Jessica P. Lakis
- Hollie Hristov
- Maia Mossé
- J. Andrés Melendez (ORCID: https://orcid.org/0000-0001-8021-3097)
- Kellyann Niotis
- Corey Saperia (ORCID: https://orcid.org/0009-0003-2598-1482)
- Helena Colvee
- Christopher Janney
- S. Murray
- Shannon Helfman
- Danny Angerbauer
- Jannatul Dishary
- Audree Rumberger
- John Westine
- Larissa Silva
- Skylar Olson
- Chelsea Brubeck
Institutions
- University of Miami (US)
- University of California, San Francisco (US)
- Stony Brook School (US)
- Watertown City School District (US)
- Institute for Neurodegenerative Disorders (US)
- Stony Brook University (US)
- Stanford University (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108643
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00